Human IGFBP4 (His Tag) recombinant protein

Human IGFBP4 (His Tag) recombinant protein

• DataSheet
• Material Safety Data Sheets (MSDS)

Insulin-like growth factor binding protein 4 (IGFBP-4) is a 24-kDa protein that binds insulin-like growth factor 1 (IGF-1) and IGF-2 with high affinity and inhibits IGF action in vitro. The Insulin-like growth factor-binding protein also known as IGFBP serves as a carrier protein for Insulin-like growth factor 1. IGFBPs are clearly distinct but are sharing regions with strong homology. All members of the IGFBP family bind IGF-I and IGF-II with about equal affinity. Insulin-like growth factor (IGF) binding proteins (IGFBPs) have been shown to either inhibit or enhance the action of IGF, or act in an IGF-independent manner in the prostate. IGF-binding protein-4 (IGFBP-4) inhibits IGF-I action in vitro and is the most abundant IGFBP in the rodent arterial wall. Expression of IGFBP-4 mRNA in nontransgenic littermates was maximal in liver and kidney. IGFBP-4 is a functional antagonist of IGF-I action on SMC. There is mounting evidence that the structure of the IGFBP proteins plays a key role in the regulation of IGF bioavailability, by modulating its molecular size, capillary membrane permeability, target tissue specificity, cell membrane adherence and IGF affinity.

Insulin-like growth factor binding protein 4, isoform CRA_a

BP-4; HT29-IGFBP; DEB2; IBP4; AI875747; IGFBP-4; IGFBP4; RP23-333D2.6

P22692

IGFBP4; hCG_1643839

Human Cells

A DNA sequence encoding the human IGFBP4 (NP_001543.2) precursor (Met 1-Glu 258) with a C-terminal polyhistidine tag was expressed.

Human

The secreted recombinant human IGFBP4 comprises 248 amino acids with a predicted molecular mass of 27.4 kDa. As a result of glycosylation, it migrates as an approximately 32 kDa band in SDS-PAGE under reducing conditions.

> 95 % as determined by SDS-PAGE

1. Measured by its ability to bind human IGF1 (Cat:10598-H24E) in functional ELISA.
2. Measured by its ability to bind human IGF2 (Cat:13032-H24E) in functional ELISA.
3. Measured by its ability to inhibit the biological activity of IGFI or IGFII on MCF7 human breast adenocarcinoma cells (Karey, K.P. et al. (1988) Cancer Research 48:4083.). The ED₅₀ for this effect is typically 0.04-0.4 μg/mL in the presence of 14 ng/mL human IGFII.